261 related articles for article (PubMed ID: 33352823)
1. How Frequently Is Asthma Objectively Demonstrated before Starting a Biologic? Quality Assessment of a Group Practice of Allergists and Immunologists.
Dziewa I; Craig T; Al-Shaikhly T
Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33352823
[TBL] [Abstract][Full Text] [Related]
2. Clinical use of biologics for asthma treatment by allergy specialists: A questionnaire survey.
Kuruvilla M; Ariue B; Oppenheimer JJ; Singh U; Bernstein JA
Ann Allergy Asthma Immunol; 2020 Oct; 125(4):433-439. PubMed ID: 32629016
[TBL] [Abstract][Full Text] [Related]
3. Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma.
Moore WC; Panettieri RA; Trevor J; Ledford DK; Lugogo N; Soong W; Chipps BE; Carr W; Belton L; Gandhi H; Trudo F; Ambrose CS
Ann Allergy Asthma Immunol; 2020 Sep; 125(3):294-303.e1. PubMed ID: 32304877
[TBL] [Abstract][Full Text] [Related]
4. Factors to Consider in Prescribing Asthma Biologic Therapies to Children.
Anderson WC; Banzon TM; Chawes B; Papadopoulos NG; Phipatanakul W; Szefler SJ
J Allergy Clin Immunol Pract; 2023 Mar; 11(3):693-701. PubMed ID: 36646381
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic?
Anderson WC; Szefler SJ
Ann Allergy Asthma Immunol; 2019 Apr; 122(4):367-372. PubMed ID: 30703438
[TBL] [Abstract][Full Text] [Related]
6. Prospects for new and emerging therapeutics in severe asthma: the role of biologics.
Kepil Özdemir S; Bavbek S
Expert Rev Respir Med; 2017 Jun; 11(6):505-512. PubMed ID: 28464704
[TBL] [Abstract][Full Text] [Related]
7. Specialty differences in the management of asthma. A cross-sectional assessment of allergists' patients and generalists' patients in a large HMO.
Vollmer WM; O'Hollaren M; Ettinger KM; Stibolt T; Wilkins J; Buist AS; Linton KL; Osborne ML
Arch Intern Med; 1997 Jun; 157(11):1201-8. PubMed ID: 9183231
[TBL] [Abstract][Full Text] [Related]
8. Severe asthma and eligibility for biologics in a Brazilian cohort.
Marques Mello L; Viana KP; Moraes Dos Santos F; Saturnino LTM; Kormann ML; Lazaridis E; Torreão CD; Soares CR; Abreu GA; Lima VB; Pinheiro GP; Lima-Matos A; Ponte EV; Mohan D; Riley JH; Cruz AA
J Asthma; 2021 Jul; 58(7):958-966. PubMed ID: 32270729
[TBL] [Abstract][Full Text] [Related]
9. The management of severe asthma in 2020.
Côté A; Godbout K; Boulet LP
Biochem Pharmacol; 2020 Sep; 179():114112. PubMed ID: 32598948
[TBL] [Abstract][Full Text] [Related]
10. Management of patients with severe asthma: results from a survey among allergists and clinical immunologists of the Central Italy Inter-Regional Section of SIAAIC.
Carli G; Farsi A; Bormioli S; Ridolo E; Fassio F; Pucci S; Montevecchi M; Riparbelli M; Cosmi L; Parronchi P; Rossi O
Clin Mol Allergy; 2021 Dec; 19(1):22. PubMed ID: 34872572
[TBL] [Abstract][Full Text] [Related]
11. A preliminary retrospective treatment and pharmacoeconomic analysis of asthma care provided by allergists, immunologists, and primary care physicians in a teaching hospital.
Frieri M; Therattil J; Dellavecchia D; Rockitter S; Pettit J; Zitt M
J Asthma; 2002 Aug; 39(5):405-12. PubMed ID: 12214894
[TBL] [Abstract][Full Text] [Related]
12. Use of biologics for the treatment of moderate-to-severe asthma: the age of personalized medicine.
Mustafa SS; Patrawala S; Khurana S
Curr Opin Pulm Med; 2022 May; 28(3):266-273. PubMed ID: 35131991
[TBL] [Abstract][Full Text] [Related]
13. Physician specialty influences important aspects of pediatric asthma management.
Aung YN; Majaesic C; Senthilselvan A; Mandhane PJ
J Allergy Clin Immunol Pract; 2014; 2(3):306-12.e5. PubMed ID: 24811022
[TBL] [Abstract][Full Text] [Related]
14. New perspectives of childhood asthma treatment with biologics.
Just J; Deschildre A; Lejeune S; Amat F
Pediatr Allergy Immunol; 2019 Mar; 30(2):159-171. PubMed ID: 30444939
[TBL] [Abstract][Full Text] [Related]
15. Biologics in pediatric lung disease.
McGhee SA
Curr Opin Pediatr; 2018 Jun; 30(3):366-371. PubMed ID: 29538045
[TBL] [Abstract][Full Text] [Related]
16. A retrospective cohort study in severe asthma describing commonly measured biomarkers: Eosinophil count and IgE levels.
Haughney J; Morice A; Blyth KG; Lee AJ; Coutts A; McKnight E; Pavord I
Respir Med; 2018 Jan; 134():117-123. PubMed ID: 29413497
[TBL] [Abstract][Full Text] [Related]
17. Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.
Godar M; Blanchetot C; de Haard H; Lambrecht BN; Brusselle G
MAbs; 2018 Jan; 10(1):34-45. PubMed ID: 29035619
[TBL] [Abstract][Full Text] [Related]
18. Treatment for Severe Asthma in Children: What About Biologics?
Pansare M; Seth D; Kamat D; Poowuttikul P
Pediatr Ann; 2021 May; 50(5):e206-e213. PubMed ID: 34044704
[TBL] [Abstract][Full Text] [Related]
19. Promises and challenges of biologics for severe asthma.
Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
[TBL] [Abstract][Full Text] [Related]
20. Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent.
Krings JG; McGregor MC; Bacharier LB; Castro M
J Allergy Clin Immunol Pract; 2019; 7(5):1379-1392. PubMed ID: 31076056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
